|
|
Expression and significance of microRNA-221 in non-small cell lung cancer |
HE Jiayong1 YANG Chenchen2 XU Qian2 |
1.NO.1 Department of Surgery, Staff-worker Hospital of Urumqi Petrochemical Subsidiary China National Petroleum, Xinjiang Uygur Autonomous Region, Urumqi 830019, China;
2.Teaching Office of Immunology, College of Preclinical Medicine, Cancer Hospital Affiliated of Xinjiang Medical University, Xinjiang Uygur Autonomous Region, Urumqi 830011, China |
|
|
Abstract Objective To investigate the expression and significance of microRNA-221 in non-small cell lung cancer (NSCLC). Methods A total of 53 NSCLC cases′ clinical material were collected from Cancer Hospital Affiliated of Xinjiang Medical University from January 2010 to January 2011, and all the cases accepted pulmonary lobectomy and systematic mediastinal lymphadenectomy. Levels of miRNA-221 in the NSCLC and adjacent tissues were examined by real-time quantitative reverse transcription polymerase chain reaction (qRT-PCR). The relationship between expression level of miRNA-221 and clinic pathological parameters were analyzed. Kaplan-Meier was used to analyze the relationship between miRNA-221 expression and overall survival (OS). Results The relative expression of miRNA-221 in NSCLC tissues was (0.0234±0.0002), and it was (0.0095±0.0003) in adjacent tissues. The relative expression of miRNA-221 in NSCLC tissues was higher than that in adjacent tissues (P < 0.05). There were 31 cases having relative higher expression. The level of miRNA-221 was significantly higher in TNM stage Ⅲ than that in TNM stage Ⅰ-Ⅱ(P < 0.05). Kaplan-Meir survival analysis results manifested that the median OS of patients with miRNA-221 high expression was 36.4 months. There was no significant difference in OS between miRNA-221 low expression and high expression patients(P > 0.05). Conclusion miRNA-221 is a potential molecular marker for the prognosis of lung cancer, which may be involved in the development and progression of NSCLC.
|
|
|
|
|
[1] 耿立国.早期非小细胞肺癌预后影响因素及预测方法研究[D].南京:南京医科大学,2017.
[2] 万海江.对一例左肺癌老年患者化疗方案优化的药学服务[J].中国农村卫生,2017,5(24):94-95.
[3] 贺加贝.NSCLC患者血浆和肿瘤组织中PD-1、PD-L1的表达水平和临床意义的研究[D].北京:北京市结核病胸部肿瘤研究所,2016.
[4] 李犹龙,范江.5种miR表达对NSCLC患者临床预后的影响[J].热带医学杂志,2016,16(12):1498-1500.
[5] 张鑫,惠越,张燕,等.MicroRNA-21与细胞损伤及凋亡的研究进展[J].重庆医学,2017,46(1):120-123.
[6] Pan YJ,Zhuang Y,Zheng JN,et al. MiR-106a:Promising biomarker for cancer [J]. ACS Med Chem Lett,2016,26(22):5373-5377.
[7] 王亚伟.RYBP在乳腺癌中的作用及相关miRNA调控机制研究[D].长春:吉林大学,2017.
[8] Qin Q,Wei F,Zhang J,et al. miR-134 suppresses the migration and invasion of non small cell lung cancer by targeting ITGB1 [J]. Oncol Rep,2017,37(2):823-830.
[9] 李锋,宋文娜,张秋月,等.探究miR-221在甲状腺乳头状癌中的表达及其与患者临床资料和预后的关系[J].养生保健指南,2017(34):49.
[10] Abak A,Amini S,Estiar MA,et al. Analysis of miRNA-221 Expression Level in Tumors and Marginal Biopsies from Patients with Breast Cancer(Cross-Sectional Observational Study)[J]. Clin Lab,2018,64(1):169-175.
[11] 叶波,杨龙海,刘向阳.最新国际肺癌TNM分期标准(第7版)修订稿解读[J].中国医刊,2008,43(1):21-23.
[12] 彭馥芝,冉茂良,翁波,等.miR-221/222基因家族进化分析及其在猪睾丸组织中的表达变化[J].经济动物学报,2017,21(1):33-40.
[13] 彭武建,谭奎璧,黄建溶.非IgA系膜增生性肾小球肾炎患者全基因组miRNA表达谱的特征[J].中国当代医药,2016,23(18):4-7.
[14] 张青,仇诚,夏东彦,等.miR-221/miR-222家族在神经胶质瘤患者脑脊液中的表达及其诊断价值[J].临床神经外科杂志,2017,14(6):401-405.
[15] 周宁.选择性抑制miR-221对卵巢癌细胞增殖、迁移能力的作用[D].石家庄:河北医科大学,2016.
[16] 尹杰,白志刚,蔡军,等.血清MicroRNA作为结直肠癌肝转移患者早期诊断标志物的探索性研究[J].临床和实验医学杂志,2016,15(2):97-101.
[17] Galardi S,Mercatelli N,Giorda E,et al. miR-221 and miR-222 Expression affects the proliferation potential of human prostate carcinoma cell lines by targeting p27Kip1 [J]. J Biol Chem,2007,282(32):23 716-23 724.
[18] 吴展陵,钟敏华.MicroRNA-221对非小细胞肺癌NCI-H1299细胞生长的影响及其机制研究[J].解放军医药杂志,2016,28(6):36-40.
[19] 吕俊杰,徐磊,许有涛,等.非小细胞肺癌组织miRNA-221表达及其与预后的关系研究[J].中国肺癌杂志,2014, 17(3):221-225.
[20] 罗家友,周凌燕,张丽娟,等.呼出气冷凝液CEA、P53蛋白、miRNA21检测对孤立性肺结节早期肺癌的诊断价值及临床相关性研究[J].中国现代医生,2018,56(7):5-8,169.
[21] 张书新,刘阳.高通量微RNA表达谱检测在肺癌临床应用中的研究进展[J].医学综述,2016,22(7):1323-1326.
[22] 靳松,黄爱军,林昆,等.miR-124靶向抑制NFATc1调控小鼠C3H10T1/2细胞软骨分化的研究[J].新医学,2018, 49(1):36-41.
[23] 林在楷,周琨,陆霁,等.ROC曲线分析miRNA-221/222作为侵袭性甲状腺乳头状癌诊断标志物的临床价值[J].癌症进展,2018,16(1):49-52.
[24] 余枭凤,张月飞.miR-203在恶性肿瘤中的作用及其相关靶基因的研究进展[J].中华实用诊断与治疗杂志,2017,31(5):506-509.
[25] Zhou L,Jiang F,Chen X,et al. Downregulation of miR-221/222 by a microRNA sponge promotes apoptosis in oral squamous cell carcinoma cells through upregulation of PTEN [J]. Oncol Lett,2016,12(6):4419-4426.
[26] 李薇,刘天华,张舒,等.肿瘤转移相关糖基转移酶表达调控研究进展[J].中国临床医学,2016,23(2):233-236. |
|
|
|